Latest news with #Foresee
Associated Press
21-05-2025
- Business
- Associated Press
Myriad Advisor Solutions Highlights the Power of Succession Planning and 4C Compliance
WAUKEE, Iowa--(BUSINESS WIRE)--May 21, 2025-- Myriad Advisor Solutions (Myriad), a long-established, full-service business advisory firm, is highlighting the power of its proven 4C compliance platform during the 2025 Trade PMR Synergy Conference in Tampa May 27-28. In addition to showcasing 4C's tested capabilities, Myriad continues to lead conversations on business continuity and succession planning through its partnership with the Exit Planning Institute, national speaking engagements, and an American City Business Journals article based on Myriad founder Leigh White's own very personal journey – one that led to the team's realization that continuity and succession planning was vital for the success of any company. Myriad is also excited to be hosting the firm's seventh annual charity golf tournament in Des Moines in June. MYRIAD'S 4C PLATFORM: A SMARTER APPROACH TO COMPLIANCE AND OPERATIONS 4C (Foresee), part of the established MASDefense suite, is Myriad's comprehensive platform, designed to help Registered Investment Advisors (RIAs) gain better control over their compliance and operational environment without adding complexity. Built in direct response to real-world advisor pain points, 4C integrates seamlessly into existing workflows and consolidates essential tools into one secure, streamlined hub. 4C focuses on four core pillars of well-run advisory business: With capabilities like CE credit tracking, audit-ready reports, and integrated cybersecurity protocols, 4C enables RIAs to simplify operations and improve audit readiness, without disrupting what already works. '4C isn't about reinventing the wheel — it's about making the ride smoother,' said Danielle White, CEO of Myriad. 'We've built this platform on everything we've learned from over 15 years of working directly with independent advisors. It's intuitive, integrated, and most importantly — it works.' Myriad will demonstrate the platform's value at the 2025 TradePMR Synergy Conference. SHARPENING THE SAW AT THE CEPA SUMMIT Myriad CTO Leigh White, CEPA®,, and CEO Danielle White, CEPA®, attended the Certified Exit Planner Association (CEPA®) 2025 Summit in May. They returned with fresh perspectives and a renewed commitment to helping business owners shape their futures. While attending the summit, White and White delved into important issues such as the following: 'Exit planning isn't just about leaving the business, it's about building a business that runs with intention, structure, and value every step of the way,' said CEO White. 'It's about creating a legacy. We are devoted to helping our clients build legacies worth leaving.' CTO White added, 'Understanding all the steps necessary to ensure a smooth transition is vital. Bringing in a specialist early can really make the difference because some of these processes must be set into motion years in advance to ensure a seamless exit.' This mission is personal for the Whites. Leigh White's own succession journey, marked by professional accomplishments and personal trials, was recently featured in American City Business Journals' 'In Her Own Words' series. Her story, along with a new Swift Chat interview with host Marie Swift, a powerful reminder that proper planning is essential not only for business continuity but also for personal peace of mind. 'In early 2021, I was diagnosed with breast cancer,' she said. 'You immediately ask yourself 'Do I have my affairs in order?' It's overwhelming, but when you've already planned for the future, it becomes a little easier to focus on what matters most, healing and hope. We are more than just the work we do, and we owe it to ourselves to prepare for life's unexpected turns.' MYRIAD CHARITY GOLF TOURNAMENT 2025 This year marks the seventh annual Myriad Charity Golf Tournament. The 2025 tournament will be held on Thursday, June 19, at Bright Grandview Golf Course in Des Moines, Iowa. It's a fun, relaxed day of golf and community, open to anyone who wants to play and support a good cause. All of the proceeds from the tournament will go directly to the Ronald McDonald House and the Iowa Narcotics Officers Association. Registration includes: Click here for details and registration information. ABOUT MYRIAD ADVISOR SOLUTIONS Established in 2009, this full-service business advisory and solutions firm has been dedicated to its mission of empowering small business owners to achieve their goals by alleviating the operational demands and challenges which growing businesses invariably face. While its focus has primarily been helping breakaway brokers go independent and independent financial advisors reach new levels of success, Myriad Advisor Solutions (Myriad) also works with other types of privately-held businesses on an individual needs-and-interests basis, providing these developing companies with all-encompassing business solutions, operational guidance, and technical support. The company has assisted in launching over 9,500 successful businesses with more than 3,200 locations established nationwide. As a part of that work, Myriad has configured and managed over 5,000 technology networks. It is the umbrella company for two subsidiary firms: Continuum Advantage (which offers with human resources, benefits, payroll, insurance, etc.) and Communications Experts (a telecommunications-focused firm). CEO Danielle White has been with the company since its inception. Leigh White, formerly CEO and President, now leads product development and remains on the leadership team. To learn more, please visit View source version on CONTACT: Media Contact: Grace Vogelzang Impact Communications, Inc. 913-649-5009 [email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA IOWA INDUSTRY KEYWORD: SECURITY DATA MANAGEMENT INSURANCE START-UP TECHNOLOGY HUMAN RESOURCES FINANCE CONSULTING SMALL BUSINESS PROFESSIONAL SERVICES ENTREPRENEUR PHILANTHROPY FUND RAISING TELECOMMUNICATIONS SOFTWARE CONSUMER SOURCE: Myriad Advisor Solutions Copyright Business Wire 2025. PUB: 05/21/2025 07:07 AM/DISC: 05/21/2025 07:06 AM
Yahoo
21-05-2025
- Business
- Yahoo
Myriad Advisor Solutions Highlights the Power of Succession Planning and 4C Compliance
Power of charitable giving driven home with Myriad's seventh annual charity golf tournament WAUKEE, Iowa, May 21, 2025--(BUSINESS WIRE)--Myriad Advisor Solutions (Myriad), a long-established, full-service business advisory firm, is highlighting the power of its proven 4C compliance platform during the 2025 Trade PMR Synergy Conference in Tampa May 27-28. In addition to showcasing 4C's tested capabilities, Myriad continues to lead conversations on business continuity and succession planning through its partnership with the Exit Planning Institute, national speaking engagements, and an American City Business Journals article based on Myriad founder Leigh White's own very personal journey – one that led to the team's realization that continuity and succession planning was vital for the success of any company. Myriad is also excited to be hosting the firm's seventh annual charity golf tournament in Des Moines in June. MYRIAD'S 4C PLATFORM: A SMARTER APPROACH TO COMPLIANCE AND OPERATIONS 4C (Foresee), part of the established MASDefense suite, is Myriad's comprehensive platform, designed to help Registered Investment Advisors (RIAs) gain better control over their compliance and operational environment without adding complexity. Built in direct response to real-world advisor pain points, 4C integrates seamlessly into existing workflows and consolidates essential tools into one secure, streamlined hub. 4C focuses on four core pillars of well-run advisory business: Compliance for evolving regulatory standards Communication that's secure, personalized, and efficient Control over data, permissions and oversight Connection between the platforms and tools RIAs rely on daily With capabilities like CE credit tracking, audit-ready reports, and integrated cybersecurity protocols, 4C enables RIAs to simplify operations and improve audit readiness, without disrupting what already works. "4C isn't about reinventing the wheel — it's about making the ride smoother," said Danielle White, CEO of Myriad. "We've built this platform on everything we've learned from over 15 years of working directly with independent advisors. It's intuitive, integrated, and most importantly — it works." Myriad will demonstrate the platform's value at the 2025 TradePMR Synergy Conference. SHARPENING THE SAW AT THE CEPA SUMMIT Myriad CTO Leigh White, CEPA®,, and CEO Danielle White, CEPA®, attended the Certified Exit Planner Association (CEPA®) 2025 Summit in May. They returned with fresh perspectives and a renewed commitment to helping business owners shape their futures. While attending the summit, White and White delved into important issues such as the following: The Value Acceleration Methodology The importance of business valuation Choosing mastery over mediocrity Why exit planning starts NOW, not when you're "ready" "Exit planning isn't just about leaving the business, it's about building a business that runs with intention, structure, and value every step of the way," said CEO White. "It's about creating a legacy. We are devoted to helping our clients build legacies worth leaving." CTO White added, "Understanding all the steps necessary to ensure a smooth transition is vital. Bringing in a specialist early can really make the difference because some of these processes must be set into motion years in advance to ensure a seamless exit." This mission is personal for the Whites. Leigh White's own succession journey, marked by professional accomplishments and personal trials, was recently featured in American City Business Journals' "In Her Own Words" series. Her story, along with a new Swift Chat interview with host Marie Swift, a powerful reminder that proper planning is essential not only for business continuity but also for personal peace of mind. "In early 2021, I was diagnosed with breast cancer," she said. "You immediately ask yourself 'Do I have my affairs in order?' It's overwhelming, but when you've already planned for the future, it becomes a little easier to focus on what matters most, healing and hope. We are more than just the work we do, and we owe it to ourselves to prepare for life's unexpected turns." MYRIAD CHARITY GOLF TOURNAMENT 2025 This year marks the seventh annual Myriad Charity Golf Tournament. The 2025 tournament will be held on Thursday, June 19, at Bright Grandview Golf Course in Des Moines, Iowa. It's a fun, relaxed day of golf and community, open to anyone who wants to play and support a good cause. All of the proceeds from the tournament will go directly to the Ronald McDonald House and the Iowa Narcotics Officers Association. Registration includes: 18 holes of golf Catered lunch Two drink tickets Awards banquet after the round Click here for details and registration information. ABOUT MYRIAD ADVISOR SOLUTIONS Established in 2009, this full-service business advisory and solutions firm has been dedicated to its mission of empowering small business owners to achieve their goals by alleviating the operational demands and challenges which growing businesses invariably face. While its focus has primarily been helping breakaway brokers go independent and independent financial advisors reach new levels of success, Myriad Advisor Solutions (Myriad) also works with other types of privately-held businesses on an individual needs-and-interests basis, providing these developing companies with all-encompassing business solutions, operational guidance, and technical support. The company has assisted in launching over 9,500 successful businesses with more than 3,200 locations established nationwide. As a part of that work, Myriad has configured and managed over 5,000 technology networks. It is the umbrella company for two subsidiary firms: Continuum Advantage (which offers with human resources, benefits, payroll, insurance, etc.) and Communications Experts (a telecommunications-focused firm). CEO Danielle White has been with the company since its inception. Leigh White, formerly CEO and President, now leads product development and remains on the leadership team. To learn more, please visit View source version on Contacts Media Contact: Grace VogelzangImpact Communications, Inc.913-649-5009GraceVogelzang@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21-05-2025
- Business
- Business Wire
Myriad Advisor Solutions Highlights the Power of Succession Planning and 4C Compliance
WAUKEE, Iowa--(BUSINESS WIRE)-- Myriad Advisor Solutions (Myriad), a long-established, full-service business advisory firm, is highlighting the power of its proven 4C compliance platform during the 2025 Trade PMR Synergy Conference in Tampa May 27-28. In addition to showcasing 4C's tested capabilities, Myriad continues to lead conversations on business continuity and succession planning through its partnership with the Exit Planning Institute, national speaking engagements, and an American City Business Journals article based on Myriad founder Leigh White's own very personal journey – one that led to the team's realization that continuity and succession planning was vital for the success of any company. Myriad is also excited to be hosting the firm's seventh annual charity golf tournament in Des Moines in June. 'We've built the 4C platform on everything we've learned from over 15 years of working directly with independent advisors. It's intuitive, integrated, and most importantly – it works.' Share MYRIAD'S 4C PLATFORM: A SMARTER APPROACH TO COMPLIANCE AND OPERATIONS 4C (Foresee), part of the established MASDefense suite, is Myriad's comprehensive platform, designed to help Registered Investment Advisors (RIAs) gain better control over their compliance and operational environment without adding complexity. Built in direct response to real-world advisor pain points, 4C integrates seamlessly into existing workflows and consolidates essential tools into one secure, streamlined hub. 4C focuses on four core pillars of well-run advisory business: Compliance for evolving regulatory standards Communication that's secure, personalized, and efficient Control over data, permissions and oversight Connection between the platforms and tools RIAs rely on daily With capabilities like CE credit tracking, audit-ready reports, and integrated cybersecurity protocols, 4C enables RIAs to simplify operations and improve audit readiness, without disrupting what already works. '4C isn't about reinventing the wheel — it's about making the ride smoother,' said Danielle White, CEO of Myriad. 'We've built this platform on everything we've learned from over 15 years of working directly with independent advisors. It's intuitive, integrated, and most importantly — it works.' Myriad will demonstrate the platform's value at the 2025 TradePMR Synergy Conference. SHARPENING THE SAW AT THE CEPA SUMMIT Myriad CTO Leigh White, CEPA®,, and CEO Danielle White, CEPA®, attended the Certified Exit Planner Association (CEPA®) 2025 Summit in May. They returned with fresh perspectives and a renewed commitment to helping business owners shape their futures. While attending the summit, White and White delved into important issues such as the following: The Value Acceleration Methodology The importance of business valuation Choosing mastery over mediocrity Why exit planning starts NOW, not when you're 'ready' 'Exit planning isn't just about leaving the business, it's about building a business that runs with intention, structure, and value every step of the way,' said CEO White. 'It's about creating a legacy. We are devoted to helping our clients build legacies worth leaving.' CTO White added, 'Understanding all the steps necessary to ensure a smooth transition is vital. Bringing in a specialist early can really make the difference because some of these processes must be set into motion years in advance to ensure a seamless exit.' This mission is personal for the Whites. Leigh White's own succession journey, marked by professional accomplishments and personal trials, was recently featured in American City Business Journals' 'In Her Own Words' series. Her story, along with a new Swift Chat interview with host Marie Swift, a powerful reminder that proper planning is essential not only for business continuity but also for personal peace of mind. 'In early 2021, I was diagnosed with breast cancer,' she said. 'You immediately ask yourself 'Do I have my affairs in order?' It's overwhelming, but when you've already planned for the future, it becomes a little easier to focus on what matters most, healing and hope. We are more than just the work we do, and we owe it to ourselves to prepare for life's unexpected turns.' MYRIAD CHARITY GOLF TOURNAMENT 2025 This year marks the seventh annual Myriad Charity Golf Tournament. The 2025 tournament will be held on Thursday, June 19, at Bright Grandview Golf Course in Des Moines, Iowa. It's a fun, relaxed day of golf and community, open to anyone who wants to play and support a good cause. All of the proceeds from the tournament will go directly to the Ronald McDonald House and the Iowa Narcotics Officers Association. Registration includes: 18 holes of golf Catered lunch Two drink tickets Awards banquet after the round Click here for details and registration information. ABOUT MYRIAD ADVISOR SOLUTIONS Established in 2009, this full-service business advisory and solutions firm has been dedicated to its mission of empowering small business owners to achieve their goals by alleviating the operational demands and challenges which growing businesses invariably face. While its focus has primarily been helping breakaway brokers go independent and independent financial advisors reach new levels of success, Myriad Advisor Solutions (Myriad) also works with other types of privately-held businesses on an individual needs-and-interests basis, providing these developing companies with all-encompassing business solutions, operational guidance, and technical support. The company has assisted in launching over 9,500 successful businesses with more than 3,200 locations established nationwide. As a part of that work, Myriad has configured and managed over 5,000 technology networks. It is the umbrella company for two subsidiary firms: Continuum Advantage (which offers with human resources, benefits, payroll, insurance, etc.) and Communications Experts (a telecommunications-focused firm). CEO Danielle White has been with the company since its inception. Leigh White, formerly CEO and President, now leads product development and remains on the leadership team. To learn more, please visit
Yahoo
15-05-2025
- Health
- Yahoo
Foresee Pharmaceuticals Announces First Patient Dosed in the Phase 2 WINDWARD Study of the ALDH2 Activator Mirivadelgat for Patients with Pulmonary Hypertension-Associated Interstitial Lung Disease (PH-ILD)
The WINDWARD study is a multinational, double-blind, 3-arm Phase 2 study to evaluate the safety and efficacy of mirivadelgat in adult subjects with PH-ILD. Mirivadelgat is a first-in-class oral small molecule with a novel mechanism of action, having the potential to provide a disease-modifying treatment for patients with PH-ILD, through its effect on both the cardiovascular and interstitial lung disease components of PH-ILD. PH-ILD is an underserved severe disease. Approximately 30% of ILD patients develop PH, with up to 100,000 diagnosed PH-ILD patients in the U.S.1 TAIPEI, May 15, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced the dosing of the first patient in the Phase 2 pulmonary hypertension-associated interstitial lung disease (PH-ILD) study (WINDWARD study). The WINDWARD study is a Phase 2, multinational, double-blind, 3-arm study to evaluate the safety and efficacy of mirivadelgat (FP-045), an oral aldehyde dehydrogenase 2 activator, in adult subjects (aged 18 to 85 years) with PH-ILD. The WINDWARD Phase 2 study is designed for 16-weeks to evaluate the safety and efficacy of mirivadelgat administered orally compared to placebo in 99 patients (33 evaluable subjects in each cohort) with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The primary endpoint will be the mean change from baseline to week-12 in the Pulmonary Vascular Resistance (PVR) assessed by right heart catheterization for mirivadelgat versus placebo in subjects with PH-ILD. Multiple secondary endpoints will be included, such as the mean change from baseline to week-12 of long-term prognostic risk factors, e.g., N-terminal pro-brain natriuretic peptide (NT-ProBNP) in subjects with PH-ILD and the mean change from baseline to week-12 of the 6-minute walk distance in subjects with PH-ILD. "Dosing of the first patient in the WINDWARD study is a testament to the dedication of our team to finding a potential therapy for patients with PH-ILD. This trial builds on rigorous foundations and incorporates a robust design to evaluate mirivadelgat 's safety and efficacy across several clinical endpoints, including improvements in Peripheral Vascular Resistance (PVR) and functional capacities in PH-ILD patients. We are committed to executing this study efficiently, generating high-quality evidence, and ensuring patient safety to advance mirivadelgat as a transformative option for patients with Pulmonary Hypertension associated Interstitial Lung Disease (PH-ILD)." Stated Bassem Elmankabadi, M.D., Senior Vice President, Clinical Development. "Mirivadelgat (FP-045) is a scientific breakthrough mechanism targeting ALDH2 activation. Preclinical data demonstrated mirivadelgat's disease modifying activity on lung fibrosis, heart hypertrophy, and fibrosis as well as pulmonary and cardiac function. The WINDWARD trial will validate its clinical impact, potentially ushering in a new treatment era for patients with limited options. This milestone underscores our leadership in leveraging cutting-edge science to improve lives." Stated Dr. Wenjin Yang, Ph.D., Chief Scientific Officer. Dr. Ben Chien, Ph.D., Chairman and CEO of Foresee Pharmaceuticals, stated: "Today's achievement reflects Foresee's unwavering mission to pioneer life-changing therapies. The initiation of Phase 2 for mirivadelgat is a strategic milestone that brings us closer to delivering hope to millions affected by the PH-ILD condition. We thank the investigators, patients, and our talented team for their relentless pursuit of innovation." About PH-ILD Pulmonary hypertension (PH) leads to abnormally high mean pulmonary arterial pressure (mPAP), and it is a complex and devastating disease that causes progressive vasoconstriction and vascular remodeling of the distal pulmonary arteries. A significant proportion of patients with Interstitial Lung Disease (ILD), a group of severe, progressive lung disorders that can damage the lungs and make it harder to breathe, such as Idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF), combined pulmonary fibrosis and emphysema (CPFE), and connective tissue disease (CTD) will develop PH as a result of their arteries in the lungs tightening so that blood can only go to areas of the lungs that are receiving the most air and oxygen. This tightening leads to high blood pressure throughout the lungs. The only approved treatment for PH-ILD is inhaled treprostinil. About Mirivadelgat Foresee is positioning mirivadelgat, as a first-in-class, once-a-day oral drug for the treatment of PH-ILD and other rare/severe diseases. Mirivadelgat and other Foresee oral ALDH2 activators have demonstrated compelling non-clinical efficacy across a broad panel of animal pharmacology and translational models, highlighting the pivotal role of ALDH2 activation in the modulation of mitochondrial stress, energetics, tissue inflammation, fibrosis, and muscle function, amongst some of its key functions. The efficacy observed in models of heart failure, pulmonary hypertension, muscle dysfuntion and pulmonary fibrosis/interstitial lung disease, is highly impressive, demonstrating disease modifying efficacy on lung fibrosis, heart hypertrophy and fibrosis as well as pulmonary and cardiac function. The body of data strongly supports the ongoing Phase 2 WINDWARD study. About Foresee Pharmaceuticals Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee's R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable (LAI) technology with derived drug products targeting specialty markets, and secondly, its transformative preclinical and clinical first-in-class oral NCE programs targeting rare and severe disease areas with high unmet needs. Foresee's product portfolio includes late and early-stage programs. CAMCEVI 42 mg, for the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan, Israel, and the UK and launched in the U.S. and Germany. The China MAA of CAMCEVI 6-month was accepted for a substantive review. Additionally, the U.S. NDA for the 3-month version of CAMCEVI has been submitted and accepted for review with a PDUFA date of August 29, 2025, and the EU regulatory submission for the 3-month version of CAMCEVI has been completed in March 2025, and accepted for scientific assessment. For the second indication of CAMCEVI 6-month LAI formulation, central precocious puberty (CPP), the Casppian Phase 3 clinical study is ongoing. CAMCEVI 6-month LAI formulation is also being developed in a Phase 3 clinical trial in premenopausal breast cancer in China in collaboration with its partner. Aderamastat (FP-025), a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 proof-of-concept study in allergic asthmatic patients. The study had positive outcomes, with future development in rare immune-fibrotic diseases. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, has completed a Phase 1 study in healthy volunteers, with development targeted at severe asthma, COPD, and IBD. Mirivadelgat (FP-045) is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients has been initiated. Building on the compelling biology of ALDH2 and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome/healthy weight loss and the broader cardiovascular-renal-metabolic space. 1 Datamonitor Healthcare 2023; Pulmonary Fibrosis Foundation; Singh et al., Circulation Research. 2022;130:1404–1422; Gupta R, et al. BMJ Open Resp Res 2023;10:e001291; Ang et al. Volume 166, Issue 4, p778-792 October 2024; View original content: SOURCE Foresee Pharmaceuticals Co., Ltd.
